Posted on February 20th, 2013 by Logan Lafferty
Dr. Lidia Schapira, of Harvard Medical School and Massachusetts General Hospital, spoke to the Mayo Clinic's Judy C. Boughey, MD, about the ACOSOG Z1071 trial, which looked at whether patients who had axillary lymph node involvement before neoadjuvant chemotherapy and who had a good response to systemic therapy could avoid axillary lymph node dissection. The provocative study was presented by Dr. Boughey at the 2012 San Antonio Breast Cancer Symposium (SABCS).
Medscape by Lidia Schapira, MD, and Judy C. Bougley, MD
Tags: axillary lymph node dissection, Breast Cancer, Dr. Judy Boughey, Dr. Lidia Schapira, Harvard Medical School, Massachusetts General Hospital, Medscape, Research, San Antonio Breast Cancer Symposium, systemic therapy
You must be logged-in to the site to post a comment.